Raia Drogasil (OTCMKTS:RADLY – Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05, Zacks reports.
Raia Drogasil Trading Up 3.3%
RADLY stock traded up $0.12 during mid-day trading on Tuesday, hitting $3.77. 2,842 shares of the company were exchanged, compared to its average volume of 54,849. Raia Drogasil has a 12-month low of $2.62 and a 12-month high of $5.34. The business has a fifty day simple moving average of $3.56 and a 200-day simple moving average of $4.23.
Analyst Ratings Changes
Separately, Zacks Research upgraded Raia Drogasil to a “hold” rating in a report on Thursday, April 9th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold”.
Raia Drogasil Company Profile
Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.
The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.
Featured Stories
- Five stocks we like better than Raia Drogasil
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
